Curaleaf Holdings, a leading international provider of cannabis consumer products, has completed the buyout of the remaining 45% stake not previously owned in Four 20 Pharma GmbH, a fully EU-GMP and GDP-licensed German producer and distributor of medical cannabis. The full acquisition strengthens Curaleaf’s vertically integrated global supply chain from owned cultivation sources in Portugal and Canada through licensed distribution across Germany.
Founded in 2020 in Paderborn, Germany, and employing 110 team members, Four 20 Pharma is recognized for high-quality cultivation, pharmaceutical-grade processing, and a comprehensive distribution network serving nursing homes, pharmacies, and research institutions. Since the initial agreement in 2022, the two companies have collaborated to expand patient access and streamline the international medical cannabis supply chain.
Building on Four 20 Pharma’s success in Germany, Curaleaf has already launched the Four 20 brand in the United Kingdom and Poland, with further international market expansion planned. Curaleaf trades on the Toronto Stock Exchange under the ticker CURA and on the OTCQX under CURLF.
KEY QUOTES:
“Completing this buyout of the remaining stake in Four 20 Pharma reinforces our commitment to Europe and underscores the strategic importance of building high-quality, locally anchored operations in a market that will continue to grow exponentially. Four 20 Pharma’s leadership in production, compliance, and distribution allows us to expand patient access to medical cannabis while driving innovation across the international market.”
Boris Jordan, CEO and Chairman, Curaleaf
“Joining the Curaleaf family as a fully integrated subsidiary marks an exciting new chapter for Four 20 Pharma. We built this company on an uncompromising commitment to quality, compliance, and patient care, values that align perfectly with Curaleaf’s international mission. Together, we are uniquely positioned to set the standard for medical cannabis across regulated markets worldwide.”
Torsten Greif, Founder and Managing Director, Four 20 Pharma
